Agios Pharmaceuticals Q2 2024 GAAP EPS $(1.69) Misses $(1.60) Estimate, Sales $8.615M Miss $9.307M Estimate
Portfolio Pulse from Benzinga Newsdesk
Agios Pharmaceuticals (NASDAQ:AGIO) reported Q2 2024 GAAP EPS of $(1.69), missing the $(1.60) estimate. Sales were $8.615M, missing the $9.307M estimate but up 28.35% YoY.
August 01, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Agios Pharmaceuticals reported Q2 2024 GAAP EPS of $(1.69), missing the $(1.60) estimate by 5.62%. Sales were $8.615M, missing the $9.307M estimate by 7.44%, but up 28.35% YoY.
The earnings and sales both missed analyst estimates, which is likely to negatively impact the stock price in the short term. However, the YoY sales increase may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100